Chemo, radiation, and immunotherapy for high-risk rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a treatment plan that combines chemotherapy, radiation, and an immunotherapy drug before surgery for people with high-risk locally advanced rectal cancer. The goal is to see if this approach can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have a type of rectal cancer called adenocarcinoma that is mismatch repair proficient (pMMR) or microsatellite stable (MSS).
- Your cancer is in the middle or lower part of the rectum (within 10 cm of the anus) and considered high-risk, meaning it has certain features like being stage T4 or involving nearby structures.
- You have not had any previous treatment for this rectal cancer, such as surgery, chemotherapy, or radiation.
- You are in generally good health (ECOG performance status 0 or 1) and have adequate organ function, as determined by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, immunotherapy (a drug that helps your immune system fight cancer), and chemotherapy before surgery for high-risk rectal cancer that has not spread. It aims to improve the chance of shrinking or eliminating the tumor before surgery.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This trial tests if adding immunotherapy to standard chemotherapy and radiation before surgery helps shrink high-risk rectal cancer and prevent it from coming back. You may be a good fit if you have a specific type of advanced rectal cancer that hasn't spread to other parts of your body.
This trial tests a combination of radiation, chemotherapy, and immunotherapy drugs before surgery for people with locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes for patients with higher-risk disease.
This trial tests whether adding two types of immunotherapy (cemiplimab with either fianlimab or REGN7075) to standard chemotherapy is safe and effective for people with locally advanced rectal cancer that has not been treated before. It may help shrink the tumor enough to allow surgery that preserves the ability to control bowel movements.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
Hear when a new Rectal Cancer, Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.